ATM and colorectal carcinoma: However, PARPi demonstrated their efficacy also when a mutation occurred in the so-called BRCAness genes, such as in ATM. Wang et al. highlighted that CRC cell lines with an ATM-inactivating mutation had an increased sensitivity to olaparib [86].